AN2 Therapeutics, Inc.

NASDAQ:ANTX

Biotechnology

Healthcare
$4.95 +0.82%

+$0.04 today

Market cap
$187.82M
Beta
-0.98
P/E (TTM)
-4.9
EPS (TTM)
-$1.01
52W Low $1.00High $6.91

Volume 0.97M

Average 0.29M

ANTX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

AN2 Therapeutics, Inc.NASDAQ: ANTX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $6.74M fell 12.3% year over year, ahead of the -28.9% change in trailing-twelve-month research & development. Sequentially, it fell 2.0% from the prior quarter. Over 3 fiscal years it compounded at -5.7% a year.

Context

  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -12.3% holds above the trailing-twelve-month pace of -28.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.74M-2.0% QoQ
Last fiscal yearDec 2025
$24.77M-38.8% YoY
LTMMar 2026
$23.82M-28.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.3%——
1 year-38.8%——
3-year CAGR-5.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
24.77M USD
Year-over-year change
-38.8%
4-year CAGR
+10.0%

Research & Development vs competitors

How ANTX compares with its peers on the latest reported figures

  • ANTX's LTM Mar 2026 research & development of $23.82M is the 3rd highest of the 6 companies compared; the peer median is $19.64M.
  • Its year-over-year change of -28.9% is the 5th highest of 6, against a peer median of +13.7%.
  • Over three fiscal years its annual growth of -5.7% compares with a peer median of -1.9%.
ANTX Competitors Peer median
Research & Development for ANTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$49.22M +63.5%-1.9%—
BOLDBoundless Bio, Inc.LTM Mar 2026$42.44M -21.4%+6.5%—
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$23.82M -28.9%-5.7%—
IBIOiBio, Inc.LTM Jun 2026$19.64M +136.3%+23.9%19643.0%
QTTBQ32 Bio Inc.LTM Mar 2026$15.25M -66.4%-18.8%28.4%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$10.43M +13.7%-10.1%28.1%
Peer median (excluding ANTX) $19.64M+13.7%-1.9%28.4%

Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue077K000
Gross Profit0(77K)000
Gross Margin—————
Research & Development16.91M29.51M54.87M40.49M24.77M
Selling, General & Admin4.67M12.75M14.76M14.07M13.34M
Operating Expenses21.57M42.19M69.64M54.55M38.11M
Depreciation & Amortization077K69.64M54.55M0
EBITDA(21.54M)(40.88M)4.9M3.23M(35.17M)
EBITDA Margin—————
Operating Income(21.57M)(42.26M)(69.64M)(54.55M)(38.11M)
Operating Margin—————
Interest Income69K1.35M4.86M5.47M2.93M
Interest Expense0514K000
Other Income / Expenses31K1.31M4.9M3.23M2.94M
Income Before Tax(21.54M)(40.96M)(64.73M)(51.32M)(35.17M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(21.54M)(40.96M)(64.73M)(51.32M)(35.17M)
Net Margin—————
EPS (Basic)(1.50)(2.79)(2.74)(1.72)(1.16)
EPS (Diluted)(1.50)(2.79)(2.74)(1.72)(1.16)
Weighted Avg Shares18.74M15.34M23.6M29.83M30.22M
Weighted Avg Shares (Diluted)18.74M15.34M23.6M29.83M30.22M

AN2 Therapeutics, Inc.

NASDAQ:ANTX

Intrinsic Alpha fair value

Locked

Current Price

$4.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.